Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
TTX-030 is a monoclonal antibody that binds to and inhibits soluble and membrane-bound ENTPD1 (CD39), resulting in decreased ATP hydrolysis, which potentially leads to activation of T-lymphocytes and anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5012).
|DrugClasses||Adenosine Targeting 18 CD39 Antibody 4|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Docetaxel + TTX-030||Docetaxel TTX-030||0||1|
|Gemcitabine + Nab-paclitaxel + TTX-030||Gemcitabine Nab-paclitaxel TTX-030||0||1|
|Pembrolizumab + TTX-030||Pembrolizumab TTX-030||0||1|